Celltrion said on Friday that it finalized a U.S. patent settlement with Johnson & Johnson (J&J), for Celltrion’s Stelara (ingredient: ustekinumab) biosimilar, CT-P43.Accordingly, the agreement allows Celltrion's CT-P43 biosimilar to enter the U.S. biosimilar market as a first-in-class product on Ma
Samsung Biologics, a global contract development and manufacturing organization (CDMO), said on Thursday that it appointed two global biopharmaceutical experts to strengthen its competitiveness in quality management and regulatory affairs. The two appointments include Gail Ward as Executive Vice Pre
Sam Chun Dang Pharmaceutical said on Thursday that it signed a $15 million licensing-out agreement to supply its biosimilar referencing Eylea (ingredient:aflibercept), SCD411, to Apotex, a Canadian pharmaceutical company. Eylea, developed by Regeneron and Bayer, treats wet age-related macular degene
Ildong Pharmaceutical said it will export benidipine hydrochloride, its cardiovascular active pharmaceutical ingredient (API), to Guangzhou Tosun Pharmaceutical in China.Benidipine hydrochloride is a calcium channel blocker (CCB) drug that blocks the movement of calcium ions involved in the contract
ANDONG -- SK bioscience said its self-developed cell-cultured flu vaccine, SKY Cellflu Quadrivalent Prefilled Syringe, has obtained national distribution approval finalizing its process for market introduction in Korea this year.SK bioscience had previously suspended production of SKY Cellflu for th
HLB said on Wednesday that its U.S. affiliate, Verismo Therapeutics, secured exclusive global rights to a binder targeting CD19, a key target antigen in blood cancers, through a license agreement with the University of Pennsylvania. HLB Group has expanded its pipeline in the field of CAR-T therapeut
The Korea Healthcare Industry Development Institute (KHIDI) said on Wednesday that healthcare exports shrunk by 18.2 percent in the first half of 2023 compared to the same period last year to reach $10.87 billion.Overall, healthcare industry exports consisting of pharmaceuticals, medical devices, an
Celltrion said in a public filing on Tuesday that it received partial approval from the European Medicines Agency (EMA) for part 1 of its global phase 3 clinical trial plan for CT-P53, its multiple sclerosis biosimilar.As of Jan. 31, the European clinical trial regulation has been amended to integra
Competition for the hemophilia A treatment market intensifies as GC Biopharma takes a shot at hemophilia A drug Hemlibra (emicizumab) sold by JW Pharmaceutical over safety concerns, and JW Pharm responds with a rebuttal.On Monday, GC distributed a press release titled "Hemlibra thrombotic adverse ev
HK inno.N's anti-cancer drug targeting non-small cell lung cancer (NSCLC) has been selected by the Korea Drug Development Foundation (KDDF) as part of the "New Drug R&D Ecosystem Building Research" project.The project is a cross-sectoral R&D program where the KDDF supports the entire life cycle of n
Genome&Company, a prominent name in the microbiome domain, has underscored its robust progress in the realm of cancer research. Genome&Company co-CEO Pae Ji-soo said the company would seek a technology transfer for two of its anticancer candidates by the year's end. This decision is attributed to du
JW Shinyak said it will resume sales of SK bioscience's influenza vaccine, SKY Cellflu Quardrivalent Prefilled Syringe.SKY Cellflu Quardrivalent is a cell-culture influenza vaccine developed by SK bioscience that protects against four types of influenza viruses -- including two types of influenza A
Hanmi Pharm has taken the first step toward clinical trials of BH3120, a double-antibody anticancer drug candidate it is developing as its next-generation pipeline.According to the Ministry of Food and Drug Safety (MFDS), Hanmi received approval for a phase 1 clinical trial of BH3120 on Friday. Hanm
JW Pharmaceutical said on Friday that it received approval to conduct phase 3 clinical trials in Taiwan for its gout drug, epaminurad (URC102).This marks the first time epaminurad has received approval for a phase 3 IND in a foreign country. The company has already submitted an IND to regulatory age
Researchers at Yonsei University College of Medicine (YUCM) have found that SGLT-2 inhibitors, commonly prescribed to diabetes patients, are effective in reducing the symptoms of non-alcoholic steatohepatitis (NASH).Non-alcoholic fatty liver disease (NAFLD) occurs due to the accumulation of fat in t
Lundbeck is drawing the industry’s attention by saying it would begin a phase 2 clinical trial of an autoimmune disease candidate it licensed in (L/I) from Korean biotech Aprilbio.Through a conference call for the first half-year on Wednesday (local time), Lundbeck announced it plans to start the ph
MSD Korea has joined hands with Seventeen, a Korean idol group, to raise awareness of the importance of HPV (human papillomavirus) prevention.The company said Thursday that it has selected global influencer Seventeen as the ambassador for its HPV prevention campaign.The company produced a TV campaig
HK inno.N said that it has entered into an exclusive distribution and co-commercialization agreement with Roche Korea for the latter's Xofluza, a once-daily antiviral treatment for influenza.Under the agreement, HK inno.N will be responsible for the distribution of Xofluza for two years, and Roche K
Lotte Healthcare said on Wednesday that it signed a memorandum of understanding (MOU) with iMediSync, a digital mental health management platform company, to jointly develop healthcare models based on artificial intelligence (AI).Founded in 2012, iMediSync specializes in the measurement of brainwave
Celltrion said on Monday that its consolidated revenue for the second quarter of this year was 524 billion won ($393 million won) and operating income was 183 billion won, down 12.1 percent and 10.1 percent year-on-year, respectively. Net profit was down 18 percent to post 151 billion won. Celltrion